# Commit Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/commit-biologics-aps

- Industry: Biotechnology
- Headquarters: Aarhus, Denmark
- Website: www.commitbio.com/
- Total disclosed funding: $48M
- Latest round: Seed (Mar 12, 2026)
- Investors on record: 3

## About

Based in Aarhus, Denmark, and founded in 2021 by co-founders Nick S. Laursen, Dennis V. Pedersen, Heidi Gytz Olesen, and Mikael Winkler, Commit Biologics ApS operates as a biotechnology research company, that develops a novel immunotherapy platform for the treatment of cancer. In March 2026, Commit Biologics ApS raised EUR 21.5 million in seed funding from Novo Holdings, Bioqube Ventures, and Korys.

Commit Biologics' portfolio is BiCE technology, a platform designed to activate the complement system against cancer cells. The company employs bi-specific antibodies to activate the complement cascade, facilitating targeted destruction of tumor cells while promoting an immune response against cancer. Its mechanism of action triggers tumor cell killing while also modulating the tumor microenvironment.
The company will use the seed funding to progress its therapies into clinical development.

## Funding rounds

- Seed, Mar 12, 2026, $25M — Novo Holdings, Korys, Bioqube Ventures
- Seed, Jan 28, 2025, $5.8M — Novo Holdings, Korys, Bioqube Ventures
- Seed, Dec 31, 2022, $17M — Novo Holdings, Bioqube Ventures

## Investors

- Novo Holdings — Seed
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Seed
- Korys (https://capitalatlas.ai/funds/korys) — Seed